Stockhead’s Ashtyn Hiron sits down with EZZ Life Science (ASX:EZZ) chairman and non-executive director Glenn Cross to close the books on 2023 and gain a sneak peek into what’s around the corner.

“FY23 was a great result for us across the board,” Cross said.

“We increased our revenue to $37.1 million, up 147% on the previous year, which was mainly attributed to our increased sales volume in China.”

Tune in to hear what’s coming up for EZZ Life Science in 2024.